公司資料
Eli Lilly 股價、新聞與催化劑
- 股票代碼:
- LLY
- 交易所:
- NYSE
- 產業:
- Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- 所在地:
- United States
股票表現
1,183.16 USD (+0.25%)
收盤價
最後更新: 2026年8月17日
949B USD
市值
股價為何變動
As of Aug 17, 2026, LLY closed up 0.25% at $1183.16. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Eli Lilly is a large-cap pharmaceutical company with major exposure to obesity, diabetes, neuroscience, and immunology. The company has become one of the market’s clearest growth stories thanks to its metabolic franchise and broad pipeline.
所在地與產業分類
Headquartered in the United States and listed on NYSE, Lilly is a global pharma company with a strong commercial presence across major markets. Its investor identity is built around growth, execution, and blockbuster product momentum.
商業模式特徵
Lilly combines blockbuster product revenue with a deep late-stage pipeline and major manufacturing investment. Investors watch demand, supply expansion, pipeline progress, and whether the company can keep scaling its metabolic and specialty franchises.
生技產業定位
Lilly sits at the top tier of large-cap healthcare because it has both scale and strong growth visibility. Compared with smaller biotech names, the stock is less binary but still highly sensitive to launch execution and pipeline durability.
未來催化劑
- Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。